1887

Abstract

We mapped three antigenic domains of continuous epitopes on human cytomegalovirus (CMV) glycoprotein B (gB) by reacting a panel of independently derived monoclonal antibodies with deletion mutants expressed transiently in COS-1 cells. One of these antigenic domains, DC2, maps in the last 75 amino acids of the carboxy terminus. These epitopes are conserved in strains Towne and AD169, as well as in 19 clinical CMV isolates. ELISAs of DC2-reactive antibodies with a set of overlapping synthetic oligopeptides from the carboxy terminus showed that the epitopes of antibodies CH405-1 and CH421-5 map between amino acids 833 and 852 and that the epitope of antibody CH28-2 maps between amino acids 878 and 898. These linear epitopes were grouped into domain DC3. The third antigenic domain, DC1, maps at the amino-terminal end of CMV strain AD169 gB but is not contained in strain Towne or in 17 of 19 clinical isolates. Epitopes in this domain are likely to map between amino acids 28 and 67, an area where differences occur in the nucleotide sequence of the gB genes from AD169 and Towne. Analysis of CMV-infected cells by flow cytometry with antibodies to the amino- and carboxy-terminal domains revealed that the amino terminus of gB is extracellular and that the carboxy terminus is not exposed on the cell surface.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-73-4-983
1992-04-01
2024-12-08
Loading full text...

Full text loading...

/deliver/fulltext/jgv/73/4/JV0730040983.html?itemId=/content/journal/jgv/10.1099/0022-1317-73-4-983&mimeType=html&fmt=ahah

References

  1. Banks T., Huo B., Kousoulas K., Spaete R., Pachl C., Pereira L. 1989; A major neutralizing domain maps within the carboxyl terminal half of the cleaved cytomegalovirus B glycoprotein. Journal of General Virology 70:979–985
    [Google Scholar]
  2. Britt W., Auger D. 1986; Synthesis and processing of the envelope gp55-116 complex of human cytomegalovirus. Journal of Virology 58:185–191
    [Google Scholar]
  3. Britt W. J., Vugler L., Stephens E. B. 1988; Induction of complement-dependent and -independent neutralizing antibodies by recombinant-derived human cytomegalovirus gp55-l16 (gB). Journal of Virology 62:3309–3318
    [Google Scholar]
  4. Britt W. J., Vugler L., Butfiloski E. J., Stevens E. J. 1990; Cell surface expression of human cytomegalovirus (HCMV) gp55-l16 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. Journal of Virology 64:1079–1085
    [Google Scholar]
  5. Chee M. S., Bankier A. T., Beck S., Bohni R., Brown C. M., Cerny R., Horsnell T., Hutchison C. A. III, Kouzarides T., Martignetti J. A., Preddie E., Satchwell S. C., Tomlinson P., Weston K. M., Barrell B. G. 1990; Analysis of the proteincoding content of the sequence of human cytomegalovirus strain AD 169. Current Topics in Microbiology and Immunology 154:126–169
    [Google Scholar]
  6. Chou S. W., Dennison K. M. 1991; Analysis of interstrain variation in cytomegalovirus glycoprotein B sequences encoding neutralization-related epitopes. Journal of Infectious Diseases 163:1229–1234
    [Google Scholar]
  7. Cranage M. P., Kousarides T., Bankier A. T., Satchwell S., Weston K., Tomlinson P., Barrell B., Hart H., Bell S. E., Minson A. C., Smith G. L. 1986; Identification of the human cytomegalovirus glycoprotein B gene and induction of neutralizing antibodies via its expression in recombinant vaccinia virus. EMHO Journal 5:3057–3063
    [Google Scholar]
  8. Cremer N., Cossen C. K., Shell G. R., Pereira L. 1985; Antibody response to cytomegalovirus polypeptides captured by monoclonal antibodies on the solid phase in enzyme immunoassays. Journal of Clinical Microbiology 21:517–521
    [Google Scholar]
  9. Drew L. 1988; Cytomegalovirus infection in patients with AIDS. Journal of Infectious Diseases 158:449–456
    [Google Scholar]
  10. Fleckenstein B., Muller I., Collins J. 1982; Cloning of the complete human cytomegalovirus genome as cosmids. Gene 18:39–46
    [Google Scholar]
  11. Gonczol E., Hudecz F., Ianacone J., Dietzschold B., Starr S., Plotkin S. A. 1986; Immune responses to isolated human cytomegalovirus envelope proteins. Journal of Virology 58:661–664
    [Google Scholar]
  12. Houghten R. A. 1985; General method for the rapid solid-phase synthesis of large numbers of peptides; specificity of antigen-antibody interaction at the level of individual amino acids. Proceedings of the National Academy of Sciences, U.S.A 82:5131–5135
    [Google Scholar]
  13. Hubenthal-Voss J., Houghten R. A., Pereira L., Roizman B. 1988; Mapping of functional domains of the a4 protein of herpes simplex virus 1. Journal of Virology 62:454–462
    [Google Scholar]
  14. Jacobson M. A., Mills J. 1988; Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Annals of Internal Medicine 108:585–594
    [Google Scholar]
  15. Kniess N., Mach M., Fay J., Britt W. J. 1991; Distribution of linear antigenic sites on glycoprotein gp55 of human cytomegalovirus. Journal of Virology 65:138–146
    [Google Scholar]
  16. Liu F., Roizman B. 1991; The promoter, transcriptional unit, and coding sequence of herpes simplex virus 1 family 35 proteins are contained within and in frame with UL26 open reading frame. Journal of Virology 65:206–212
    [Google Scholar]
  17. Mach M., Utz U., Fleckenstein B. 1986; Mapping of the major glycoprotein gene of human cytomegalovirus. Journal of General Virology 67:1461–1467
    [Google Scholar]
  18. Meyer H., Mach M. 1991; The glycoprotein gp116 of human cytomegalovirus contains two antibody binding sites in close proximity. Journal of Cellular Biochemistry supplement 15E101
    [Google Scholar]
  19. Meyer H., Masuho Y., Mach M. 1990; The gp116 of the gp58/l 16 complex of human cytomegalovirus represents the amino-terminal part of the precursor molecule and contains a neutralizing epitope. Journal of General Virology 71:2443–2450
    [Google Scholar]
  20. Meyers J. D. 1985; Cytomegalovirus infection after organ allografting. In The Herpesviruses p 201 Edited by Roizman B., Lopez C. New York: Plenum Press;
    [Google Scholar]
  21. Pereira L., Hoffman M. 1986; Immunology of human cytomegalovirus glycoproteins. In Human Herpesvirus Infections: Pathogenesis, Diagnosis, and Treatment pp 69–92 Edited by Lopez C., Roizman B. New York: Raven Press;
    [Google Scholar]
  22. Pereira L., Hoffman M., Cremer N. 1982; Electrophoretic analysis of polypeptides immune precipitated from extracts of cytomegalovirus infected cells by human sera. Infection and Immunity 36:933–942
    [Google Scholar]
  23. Pereira L., Stagno S., Hoffman M., Volanakis J. 1983; Cytomegalovirus infected cell polypeptides immune precipitated by children with congenital and perinatal cytomegalovirus infections. Infection and Immunity 39:100–108
    [Google Scholar]
  24. Pereira L., Hoffman M., Tatsuno M., Dondero D. 1984; Polymorphism of human cytomegalovirus glycoproteins characterized by monoclonal antibodies. Virology 139:73–86
    [Google Scholar]
  25. Pereira L., Ali M., Kousoulas K., Huo B., Banks T. 1989; Domain structure of herpes simplex virus 1 glycoprotein B: neutralizing epitopes map in regions of continuous and discontinuous residues. Virology 172:11–24
    [Google Scholar]
  26. Rasmussen L. 1990; Immune response to human cytomegalovirus infection. Current Topics in Microbiology and Immunology 154:221–254
    [Google Scholar]
  27. Rasmussen L., Mullenax J., Nelson R., Merigan T. C. 1985a; Human cytomegalovirus polypeptides stimulate neutralizing antibody in vivo . Virology 145:186–190
    [Google Scholar]
  28. Rasmussen L., Mullenax J., Nelson R., Merigan T. C. 1985b; Viral polypeptides detected by a complement-dependent neutralizing murine monoclonal antibody to human cytomegalovirus. Journal of Virology 55:274–280
    [Google Scholar]
  29. Rasmussen L., Nelson M., Neff M., Merigan T. C. 1988; Characterization of two different human cytomegalovirus glycoproteins which are targets for virus neutralizing antibody. Virology 163:309–318
    [Google Scholar]
  30. Rasmussen L., Matkin C., Spaete R., Pachl C., Merigan T. C. 1991; Antibody response to human cytomegalovirus glycoproteins gB and gH after natural infection in humans. Journal of Infectious Diseases 164:835–842
    [Google Scholar]
  31. Spaete R. R., Thayer R. M., Probert W. S., Masiarz F. R., Chamberlain S. H., Rasmussen L., Merigan T. C., Pachl C. 1988; Human cytomegalovirus strain Towne glycoprotein B is processed by proteolytic cleavage. Virology 167:207–225
    [Google Scholar]
  32. Spaete R. R., Saxena A., Scott L. P., Song G. J., Probert W. S., Britt W. J., Gibson W., Rasmussen L., Pachl C. 1990; Sequence requirements for proteolytic processing of glycoprotein B of human cytomegalovirus strain Towne. Journal of Virology 64:2922–2931
    [Google Scholar]
  33. Stagno S., Reynolds D. W., Huang E.-S., Thames S. D., Smith R. J., Alford C. A. 1977; Congenital cytomegalovirus infection. New England Journal of Medicine 296:1254–1258
    [Google Scholar]
  34. Stagno S., Pass R. F., Dworsky M. E., Alford C. A. 1982a; Maternal cytomegalovirus infection and perinatal transmission. Clinical Obstetrics and Gynecology 25:563–576
    [Google Scholar]
  35. Stagno S., Pass R. F., Dworsky M. E., Henderson R. E., Moore E. G., Walton P. D., Alford C. A. 19826; Congenital cytomegalovirus infection. New England Journal of Medicine 306:945–949
    [Google Scholar]
  36. Utz U., Britt W., Vugler L., Mach M. 1989; Identification of a neutralizing epitope on glycoprotein gp58 of human cytomegalovirus. Journal of Virology 63:1995–2001
    [Google Scholar]
  37. Wong G. G., Witek J. S., Temple P. A., Wilkens K. M., Leary A. C., Luxenberg D. P., Jones S. S., Brown E. L., Kay R. M., Orr E. C., Shoemaker C., Golds D. W., Kaufman R. J., Hewick R. M., Wang E. A., Clark S. C. 1985; Human GM-CSF: molecular cloning of the complementary DNA and purification of the natural and recombinant proteins. Science 228:810–812
    [Google Scholar]
/content/journal/jgv/10.1099/0022-1317-73-4-983
Loading
/content/journal/jgv/10.1099/0022-1317-73-4-983
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error